Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N

Antiviral Research

Volumn 80, Issue 3, 2008, Pages 266-271

  Smee, Donald F ^a   Bailey, Kevin W ^a   Wong, Min Hui ^a   O'Keefe, Barry R ^b   Gustafson, Kirk R ^b   Mishin, Vasiliy P ^c   Gubareva, Larisa V ^c  

^a UTAH STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Antiviral; Cyanovirin N; Ferrets; Hemagglutinin; Influenza; Mice

Indexed keywords

CYANOVIRIN N; MANNOSE OLIGOSACCHARIDE; PLACEBO; RIBAVIRIN; VIRUS HEMAGGLUTININ;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; FERRET; GENE MUTATION; GENETIC REASSORTMENT; GLYCOSYLATION; INFLUENZA; INFLUENZA VIRUS A H1N1; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS STRAIN; VIRUS TITRATION;

ANIMALS; ANTIVIRAL AGENTS; BACTERIAL PROTEINS; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION ROUTES; FEMALE; FERRETS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C;

ANIMALIA; INFLUENZA A VIRUS; MUS; MUSTELA; NOSTOC ELLIPSOSPORUM; ORTHOMYXOVIRIDAE;

EID: 56349088765     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.06.003     Document Type: Article

References (24)

1. Balzarini J. Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?. Antivir. Chem. Chemother. 18 (2007) 1-11
2. Barrientos L.G., O'Keefe B.R., Bray M., Sanchez A., Gronenborn A.M., and Boyd M.R. Cyanovirin-N binds to the viral surface glycoprotein, GP1, 2 and inhibits infectivity of Ebola virus. Antivir. Res. 58 (2003) 47-56
3. Boyd M.R., Gustafson K.R., McMahon J.B., Shoemaker R.H., O'Keefe B.R., Mori T., Gulakowski R.J., Wu L., Rivera M.I., Laurencot C.M., Currens M.J., Cardellina II J.H., Buckheit Jr. R.W., Nara P.L., Pannell L.K., Sowder II R.C., and Henderson L.E. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob. Agents Chemother. 41 (1997) 1521-1530
4. Eichelberger M.C. The cotton rat as a model to study influenza pathogenesis and immunity. Viral Immunol. 20 (2007) 243-249
5. Fenton R.J., Bessell C., Spilling C.R., and Potter C.W. The effects of peroral or local aerosol administration of 1-aminoadamantane hydrochloride (amantadine hydrochloride) on influenza infections of the ferret. J. Antimicrob. Chemother. 3 (1977) 463-472
6. Hoffmann E., Neumann G., Kawaoka Y., Hobom G., and Webster R.G. A DNA transfection system for generation of influenza A virus from eight plasmids. PNAS 97 (2000) 6108-6113
7. Mendel D.B., Tai C.Y., Escarpe P.A., Li W., Sidwell R.W., Huffman J.H., Sweet C., Jakeman K.J., Merson J., Lacy S.A., Lew W., Williams M.A., Zhang L., Chen M.S., Bischofberger N., and Kim C.U. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob. Agents Chemother. 42 (1998) 640-646
8. Mishin V.P., Nedyalkova M.S., Hayden F.G., and Gubareva L.V. Protection afforded by intranasal immunization with the neuraminidase-lacking mutant of influenza A virus in a ferret model. Vaccine 23 (2005) 2922-2927
9. Mishin V.P., Novikov D., Hayden F.G., and Gubareva L.V. Effect of hemagglutinin glycosylation on influenza virus susceptibility to neuraminidase inhibitors. J. Virol. 79 (2005) 12416-12424
10. Mori T., Gustafson K.R., Pannell L.K., Shoemaker R.H., Wu L., McMahon J.B., and Boyd M.R. Recombinant production of cyanovirin-N, a potent human immunodeficiency virus-inactivating protein derived from a cultured cyanobacterium. Protein Expr. Purif. 12 (1998) 151-158
11. O'Keefe B.R., Smee D.F., Turpin J.A., Saucedo C.J., Gustafson K.R., Mori T., Blakeslee D., Buckheit R., and Boyd M.R. Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin. Antimicrob. Agents Chemother. 47 (2003) 2518-2525
12. Potter C.W., McLaren C., and Jennings R. Assessment of resistance to influenza virus infection in animal models. Dev. Biol. Stand. 28 (1975) 307-318
13. Reed L.J., and Muench H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27 (1938) 493-497
14. Shenoy S.R., O'Keefe B.R., Bolmstedt A.J., Cartner L.K., and Boyd M.R. Selective interactions of the human immunodeficiency virus-inactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins. J. Pharmacol. Exp. Ther. 297 (2001) 704-710
15. Sidwell R.W., and Smee D.F. In vitro and in vivo assay systems for study of influenza virus inhibitors. Antivir. Res. 48 (2000) 1-16
16. Sidwell R.W., Smee D.F., Huffman J.H., Barnard D.L., Bailey K.W., Morrey J.D., and Babu Y.S. In vivo virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RWJ-201201. Antimicrob. Agents Chemother. 45 (2001) 749-757
17. Sidwell R.W., Bailey K.W., Wong M.-H., Barnard D.L., and Smee D.F. In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antivir. Res. 68 (2005) 10-17
18. Smee D.F., Wandersee M.K., Wong M.-H., Bailey K.W., and Sidwell R.W. Treatment of mannan-enhanced influenza B virus infections in mice with oseltamivir, ribavirin, and viramidine. Antivir. Chem. Chemother. 15 (2004) 261-268
19. Smee D.F., Wandersee M.K., Checketts M.B., O'Keefe B.R., Saucedo C., Boyd M.R., Mishin V.P., and Gubareva L.V. Influenza A (H1N1) virus resistance to cyanovirin-N arises naturally during adaptation to mice and by cell culturing in the presence of the inhibitor. Antivir. Chem. Chemother. 18 (2007) 317-327
20. Sweet C., Hayden F.G., Jakeman K.J., Grambas S., and Hay A.J. Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets. J. Infect. Dis. 164 (1991) 969-972
21. Sweet C., Jakeman K.J., Bush K., Wagaman P.C., McKown L.A., Streeter A.J., Desai-Krieger D., Chand P., and Babu Y.S. Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection. Antimicrob. Agents Chemother. 46 (2002) 996-1004
22. Tsai C.C., Emau P., Jiang Y., Tian B., Morton W.R., Gustafson K.R., and Boyd M.R. Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89. 6P in macaques. AIDS Res. Hum. Retroviruses 19 (2003) 535-541
23. Tsai C.C., Emau P., Jiang Y., Agy M.B., Shattock R.J., Schmidt A., Morton W.R., Gustafson K.R., and Boyd M.R. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res. Hum. Retroviruses 20 (2004) 11-18
24. Tumpey T.M., Maines T.R., Van Hoeven N., Glaser L., Solorzano A., Pappas C., Cox N.J., Swayne D.E., Palese P., Katz J.M., and Garcia-Sastre A. A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission. Science 315 (2007) 655-659